. Concernant-le-troisième-groupe, seize patients ont été traités pour une première rechute. Trois patients ont rechuté mais leur rechute n'a pas nécessité de traitement. Huit patients ont été traités par corticothérapie

G. Moulis, M. Lapeyre-mestre, D. Adoue, and L. Sailler, Épidémiologie et pharmacoépidémiologie du purpura thrombopénique immunologique. Httpwwwem-Premiumcomdocelecu- Bordeauxfrdatarevues02488663unassignS0248866316310554, 2017.

F. Rodeghiero, R. Stasi, T. Gernsheimer, M. Michel, D. Provan et al., Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group, Blood, vol.113, issue.11, pp.2386-93, 2009.
DOI : 10.1182/blood-2008-07-162503

M. Schoonen, W. Kucera, G. Coalson, J. Li, L. Rutstein et al., Epidemiology of immune thrombocytopenic purpura in the General Practice Research Database, British Journal of Haematology, vol.94, issue.Suppl 2, pp.235-279, 2009.
DOI : 10.1136/jamia.1997.0040465

G. Moulis, A. Palmaro, J. Montastruc, B. Godeau, M. Lapeyre-mestre et al., Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France, Blood, vol.124, issue.22, pp.3308-3323, 2014.
DOI : 10.1182/blood-2014-05-578336

C. Neunert, W. Lim, M. Crowther, A. Cohen, L. Solberg et al., The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood, pp.4190-207, 2011.

D. Provan, R. Stasi, A. Newland, V. Blanchette, P. Bolton-maggs et al., International consensus report on the investigation and management of primary immune thrombocytopenia. Blood, pp.168-86, 2010.

H. Autorité-de-santé-ald, 2 -Purpura thrombopénique immunologique de l'enfant et de l'adulte [Internet] Available from: https, 2017.

M. Fiore, X. Pillois, S. Lorrain, M. Bernard, N. Moore et al., A diagnostic approach that may help to discriminate inherited thrombocytopenia from chronic immune thrombocytopenia in adult patients, Platelets, vol.88, issue.6, pp.555-62, 2016.
DOI : 10.1111/bjh.13444

F. Rodeghiero, M. Michel, T. Gernsheimer, M. Ruggeri, V. Blanchette et al., Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group, Blood, vol.121, issue.14, pp.2596-606, 2013.
DOI : 10.1182/blood-2012-07-442392

G. Frydman, N. Davis, P. Beck, and J. Fox, Eradication in Patients with Immune Thrombocytopenic Purpura: A Review and the Role of Biogeography, Helicobacter, vol.3, issue.Pt 2, pp.239-51, 2015.
DOI : 10.4236/ojbd.2013.31007

P. Olbermann, C. Josenhans, Y. Moodley, M. Uhr, C. Stamer et al., A Global Overview of the Genetic and Functional Diversity in the Helicobacter pylori cag Pathogenicity Island, PLoS Genetics, vol.188, issue.8, p.1001069, 2010.
DOI : 10.1371/journal.pgen.1001069.s007

K. Sheema, U. Ikramdin, N. Arshi, N. Farah, and S. Imran, Eradication Therapy on Platelet Recovery in Chronic Immune Thrombocytopenic Purpura, Gastroenterology Research and Practice, vol.7, issue.2, p.9529752, 2017.
DOI : 10.3109/09537104.2014.911836

M. Kuwana, -associated immune thrombocytopenia: Clinical features and pathogenic mechanisms, World Journal of Gastroenterology, vol.20, issue.3, pp.714-737, 2014.
DOI : 10.3748/wjg.v20.i3.714

T. Brighton, S. Evans, P. Castaldi, C. Chesterman, and B. Chong, Prospective evaluation of the clinical usefulness of an antigen-specific assay (MAIPA) in idiopathic thrombocytopenic purpura and other immune thrombocytopenias, Blood, vol.88, issue.1, pp.194-201, 1996.

V. Kiefel, S. Santoso, M. Weisheit, and C. Müeller-eckhardt, Monoclonal antibody--specific immobilization of platelet antigens (MAIPA): a new tool for the identification of plateletreactive antibodies, Blood, vol.70, issue.6, pp.1722-1728, 1987.

L. Grimaldi-bensouda, C. Nordon, M. Michel, J. Viallard, D. Adoue et al., Immune thrombocytopenia in adults: a prospective cohort study of clinical features and predictors of outcome, Haematologica, vol.101, issue.9, pp.1039-1084, 2016.
DOI : 10.3324/haematol.2016.146373

URL : https://hal.archives-ouvertes.fr/hal-01477311

B. Godeau and . Purpura-thrombopénique-immunologique, Httpwwwem-Premiumcomdocelecu- Bordeauxfrdatatraitessa13-68194 [Internet], 2015.

A. Sarpatwari, D. Provan, S. Erqou, R. Sobnack, D. Tai et al., Autologous 111In-labelled platelet sequestration studies in patients with primary immune thrombocytopenia (ITP) prior to splenectomy: a report from the United Kingdom ITP Registry, British Journal of Haematology, vol.183, issue.Suppl. 1, pp.477-87, 2010.
DOI : 10.1016/S0140-6736(77)90132-5

L. Gugliotta, G. Isacchi, A. Guarini, F. Ciccone, M. Motta et al., Chronic Idiopathic Thrombocytopenic Purpura (ITP): Site of Platelet Sequestration and Results of Splenectomy, Scandinavian Journal of Haematology, vol.10, issue.5, pp.407-419, 1981.
DOI : 10.1111/j.1600-0609.1973.tb00067.x

Y. Najean and N. Ardaillou, The Sequestration Site of Platelets in Idiopathic Thrombocytopenic Purpura: its Correlation with the Results of Splenectomy, British Journal of Haematology, vol.171, issue.2, pp.153-64, 1971.
DOI : 10.1097/00000441-196712000-00002

I. Altomare, K. Cetin, S. Wetten, and J. Wasser, Rate of bleeding-related episodes in adult patients with primary immune thrombocytopenia: a retrospective cohort study using a large administrative medical claims database in the US, Clin Epidemiol, vol.8, pp.231-240, 2016.

C. Neunert, N. Noroozi, G. Norman, G. Buchanan, J. Goy et al., Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review, Journal of Thrombosis and Haemostasis, vol.25, issue.Suppl. 1, pp.457-64
DOI : 10.1097/00043426-200312001-00017

D. Arnold, Platelet count or bleeding as the outcome in ITP trials?, American Journal of Hematology, vol.29, issue.10, pp.945-951, 2012.
DOI : 10.1002/sim.3818

N. Cooper, State of the art - how I manage immune thrombocytopenia, British Journal of Haematology, vol.76, issue.(4 Pt 2), pp.39-54
DOI : 10.1111/j.1600-0609.2005.00622.x

M. Khellaf, M. Michel, A. Schaeffer, P. Bierling, and B. Godeau, Assessment of a therapeutic strategy for adults with severe autoimmune thrombocytopenic purpura based on a bleeding score rather than platelet count, Haematologica, vol.90, issue.6, pp.829-861, 2005.

G. Buchanan and L. Adix, Grading of hemorrhage in children with idiopathic thrombocytopenic purpura, The Journal of Pediatrics, vol.141, issue.5, pp.683-691, 2002.
DOI : 10.1067/mpd.2002.128547

W. Huang, L. S. Chang, D. Lu, J. Cheng, and S. , Monozygotic twins concordant for idiopathic thrombocytopenic purpura and discordant for systemic lupus erythematosus and lupus nephritis, European Journal of Pediatrics, vol.19, issue.5, pp.497-500, 2007.
DOI : 10.1007/s00431-006-0266-1

A. Bergmann, R. Grace, and E. Neufeld, Genetic studies in pediatric ITP: outlook, feasibility, and requirements, Annals of Hematology, vol.76, issue.S1, pp.95-103, 2010.
DOI : 10.1007/s00277-009-0865-9

M. Yong, W. Schoonen, L. Li, G. Kanas, J. Coalson et al., Epidemiology of paediatric immune thrombocytopenia in the General Practice Research Database, British Journal of Haematology, vol.94, issue.Suppl, pp.855-64, 2010.
DOI : 10.1080/08880010050122816

G. Moulis, S. Guénin, N. Limal, M. Michel, P. Bierling et al., Seasonal variations of incident primary immune thrombocytopenia in adults: An ecological study, European Journal of Internal Medicine, vol.37, pp.26-34, 2017.
DOI : 10.1016/j.ejim.2016.09.025

M. Blanchette and J. Freedman, The history of idiopathic thrombocytopenic purpura (ITP) Transfus Sci, pp.231-237, 1998.

R. He, D. Reid, C. Jones, and N. Shulman, Extracellular epitopes of platelet glycoprotein Ib alpha reactive with serum antibodies from patients with chronic idiopathic thrombocytopenic purpura. Blood, Nov, vol.1586, issue.10, pp.3789-96, 1995.

A. Zufferey, R. Kapur, and J. Semple, Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP) Available from, J Clin Med [Internet]. 2017 Feb, vol.96, issue.2, 5332920.

D. Nugent, R. Mcmillan, J. Nichol, and S. Slichter, Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and/or decreased platelet production, British Journal of Haematology, vol.76, issue.Suppl 2, pp.585-96, 2009.
DOI : 10.1007/978-1-4612-3958-1_22

X. Zhu, Y. Shi, J. Peng, C. Guo, N. Shan et al., The effects of BAFF and BAFF-R-Fc fusion protein in immune thrombocytopenia, Blood, vol.114, issue.26, pp.5362-5369, 2009.
DOI : 10.1182/blood-2009-05-217513

T. Wang, H. Zhao, H. Ren, J. Guo, M. Xu et al., Type 1 and type 2 T-cell profiles in idiopathic thrombocytopenic purpura, Haematologica, vol.90, issue.7, pp.914-937, 2005.

F. Panitsas, M. Theodoropoulou, A. Kouraklis, M. Karakantza, G. Theodorou et al., Adult chronic idiopathic thrombocytopenic purpura (ITP) is the manifestation of a type-1 polarized immune response, Blood, vol.103, issue.7, pp.2645-2652, 2004.
DOI : 10.1182/blood-2003-07-2268

J. Semple, T cell and cytokine abnormalities in patients with autoimmune thrombocytopenic purpura, Transfusion and Apheresis Science, vol.28, issue.3, pp.237-279, 2003.
DOI : 10.1016/S1473-0502(03)00041-7

Y. Hu, H. Li, L. Zhang, B. Shan, X. Xu et al., Elevated profiles of Th22 cells and correlations with Th17 cells in patients with immune thrombocytopenia, Human Immunology, vol.73, issue.6, pp.629-664
DOI : 10.1016/j.humimm.2012.04.015

F. Zhang, X. Chu, L. Wang, Y. Zhu, L. Li et al., Cell-mediated lysis of autologous platelets in chronic idiopathic thrombocytopenic purpura, European Journal of Haematology, vol.93, issue.5, pp.427-458, 2006.
DOI : 10.1084/jem.185.5.855

B. Olsson, P. Andersson, M. Jernås, S. Jacobsson, B. Carlsson et al., T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura, Nature Medicine, vol.9, issue.9, pp.1123-1127, 2003.
DOI : 10.1038/nm921

S. Audia, M. Rossato, K. Santegoets, S. Spijkers, C. Wichers et al., Splenic TFH expansion participates in B-cell differentiation and antiplatelet-antibody production during immune thrombocytopenia. Blood, pp.2858-66, 2014.
DOI : 10.1182/blood-2014-03-563445

URL : http://www.bloodjournal.org/content/bloodjournal/124/18/2858.full.pdf

T. Nishimoto and M. Kuwana, CD4+CD25+Foxp3+ Regulatory T Cells in the Pathophysiology of Immune Thrombocytopenia, Seminars in Hematology, vol.50, pp.43-52, 2013.
DOI : 10.1053/j.seminhematol.2013.03.018

L. Catani, D. Sollazzo, S. Trabanelli, A. Curti, C. Evangelisti et al., Decreased expression of indoleamine 2,3-dioxygenase 1 in dendritic cells contributes to impaired regulatory T cell development in immune thrombocytopenia, Annals of Hematology, vol.300, issue.suppl 5, pp.67-78, 2013.
DOI : 10.1016/j.ijmm.2009.08.010

R. Emmons, D. Reid, R. Cohen, G. Meng, N. Young et al., Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction, Blood, vol.87, issue.10, pp.4068-71, 1996.

K. Hoffmeister and H. Falet, Platelet clearance by the hepatic Ashwell-Morrell receptor: mechanisms and biological significance, Thrombosis Research, vol.141, issue.2, pp.68-72
DOI : 10.1016/S0049-3848(16)30370-X

D. Kuter, Milestones in understanding platelet production: a historical overview, British Journal of Haematology, vol.80, issue.2, pp.248-58, 2014.
DOI : 10.1111/j.1365-2141.1999.01359.x

É. Rivière, J. Viallard, A. Guy, B. Kilani, J. Vieira-dias et al., Intrinsically impaired platelet production in some patients with persistent or chronic immune thrombocytopenia, British Journal of Haematology, vol.97, issue.Pt 1
DOI : 10.1093/annonc/mdq233

R. Mcmillan, L. Wang, A. Tomer, J. Nichol, and J. Pistillo, Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood, Feb, vol.15103, issue.4, pp.1364-1373, 2004.

F. Génolini, C. Rochard, S. Ducassou, Y. Perel, and N. Aladjidi, Sport et maladie rare : le purpura thrombopénique immunologique (PTI) Rev Oncol Hématologie Pédiatrique, pp.134-142, 2015.

L. Grimaldi-bensouda, M. Michel, E. Aubrun, P. Leighton, J. Viallard et al., A case-control study to assess the risk of immune thrombocytopenia associated with vaccines. Blood, pp.4938-4982, 2012.

F. Buttgereit, M. Wehling, and G. Burmester, A new hypothesis of modular glucocorticoid actions: Steroid treatment of rheumatic diseases revisited, Arthritis & Rheumatism, vol.16, issue.5, pp.761-768, 1998.
DOI : 10.1016/S0165-6147(00)89021-5

M. Chambrun, . De, B. Wechsler, and S. D. Corticothérapie, Httpwwwem- Premiumcomdocelecu-Bordeauxfrdatatraitestmtm-49792 [Internet], p.51, 2013.

J. Li, Z. Wang, S. Hu, X. Zhao, and L. Cao, Correction of abnormal T cell subsets by high-dose dexamethasone in patients with chronic idiopathic thrombocytopenic purpura, Immunology Letters, vol.154, issue.1-2, pp.42-50, 2013.
DOI : 10.1016/j.imlet.2013.08.006

A. Coutinho and K. Chapman, The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights, Molecular and Cellular Endocrinology, vol.335, issue.1, pp.2-13, 2011.
DOI : 10.1016/j.mce.2010.04.005

C. Majoor, M. Sneeboer, A. De-kievit, J. Meijers, T. Van-der-poll et al., The influence of corticosteroids on hemostasis in healthy subjects, Journal of Thrombosis and Haemostasis, vol.69, issue.4, 2016.
DOI : 10.1097/00007890-200005270-00026

L. Freund, D. Berild, and B. Hainau, Haemostatic Effect of Prednisolone in Thrombocytopenia, Scandinavian Journal of Haematology, vol.46, issue.5, pp.485-492, 1983.
DOI : 10.1111/j.1600-0609.1983.tb01548.x

C. Kitchens and L. Weiss, Ultrastructural changes of endothelium associated with thrombocytopenia. Blood, pp.567-78, 1975.

B. Godeau and P. Bierling, High-dose dexamethasone as initial treatment for immune thrombocytopenic purpura, N Engl J Med, vol.349, issue.23, pp.2267-2268, 2003.

Y. Cheng, R. Wong, Y. Soo, C. Chui, F. Lau et al., Initial Treatment of Immune Thrombocytopenic Purpura with High-Dose Dexamethasone, New England Journal of Medicine, vol.349, issue.9, 2003.
DOI : 10.1056/NEJMoa030254

J. Bussel and L. Pham, Intravenous Treatment with Gammaglobulin in Adults with Immune Thrombocytopenic Purpura: Review of the Literature, Vox Sanguinis, vol.103, issue.Suppl. 1, pp.206-217, 1987.
DOI : 10.1111/j.1600-0609.1983.tb00662.x

C. Galeotti, S. Kaveri, and J. Bayry, IVIG-mediated effector functions in autoimmune and inflammatory diseases, International Immunology, 2017.
DOI : 10.1093/intimm/dxx039

L. Mouthon, G. Bussone, and S. Kaveri, Indications et m??canismes d???action des immunoglobulines intraveineuses dans les pathologies auto-immunes et inflammatoires syst??miques, La Revue de M??decine Interne, vol.30, issue.12
DOI : 10.1016/S0248-8663(09)73168-6

B. Mayer, F. Depré, F. Ringel, and A. Salama, New aspects on the efficacy of high-dose intravenous immunoglobulins in patients with autoimmune thrombocytopenia. Vox Sang, pp.64-73, 2017.

P. Bierling and B. Godeau, Intravenous Immunoglobulin for Autoimmune Thrombocytopenic Purpura, Human Immunology, vol.66, issue.4, pp.387-94, 2005.
DOI : 10.1016/j.humimm.2005.01.024

A. Lazarus, J. Freedman, and J. Semple, Intravenous immunoglobulin and Anti-D in Idiopathic Thrombocytopenic Purpura (ITP): Mechanisms of Action, Transfusion Science, vol.19, issue.3, pp.289-94, 1998.
DOI : 10.1016/S0955-3886(98)00043-5

A. Gaines, Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria following Rho(D) immune globulin intravenous administration for immune thrombocytopenic purpura, Blood, vol.106, issue.5, pp.1532-1539, 2005.
DOI : 10.1182/blood-2004-11-4303

M. Tarantino, G. Young, S. Bertolone, K. Kalinyak, F. Shafer et al., Single dose of anti-D immune globulin at 75??g/kg is as effective as intravenous immune globulin at rapidly raising the platelet count in newly diagnosed immune thrombocytopenic purpura in children, The Journal of Pediatrics, vol.148, issue.4, pp.489-94, 2006.
DOI : 10.1016/j.jpeds.2005.11.019

A. Cuker and D. Cines, Evidence-Based Mini-Review: Is Indium-Labeled Autologous Platelet Scanning Predictive of Response to Splenectomy in Patients With Chronic Immune Thrombocytopenia?, Hematology, vol.2010, issue.1, pp.385-391, 2010.
DOI : 10.1182/asheducation-2010.1.385

K. Kojouri, S. Vesely, D. Terrell, and J. George, Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications, Blood, vol.104, issue.9, pp.2623-2657, 2004.
DOI : 10.1182/blood-2004-03-1168

C. Chater, L. Terriou, A. Duhamel, D. Launay, J. Chambon et al., Reemergence of Splenectomy for ITP Second-line Treatment? Ann Surg, pp.772-779, 2016.

W. Ghanima, B. Godeau, D. Cines, and J. Bussel, How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment, Blood, vol.120, issue.5, 2012.
DOI : 10.1182/blood-2011-12-309153

Y. Guan, S. Wang, F. Xue, X. Liu, L. Zhang et al., Long-term results of splenectomy in adult chronic immune thrombocytopenia, European Journal of Haematology, vol.373, issue.3, pp.235-276, 2017.
DOI : 10.1016/S0140-6736(09)60402-5

R. Ahmed, A. Devasia, A. Viswabandya, K. Lakshmi, A. Abraham et al., Long-term outcome following splenectomy for chronic and persistent immune thrombocytopenia (ITP) in adults and children, Annals of Hematology, vol.120, issue.5, pp.1429-1463, 2016.
DOI : 10.1182/blood-2011-12-309153

O. Akwari, K. Itani, R. Coleman, and W. Rosse, Splenectomy for primary and recurrent immune thrombocytopenic purpura (ITP) Current criteria for patient selection and results

J. Navez, C. Hubert, J. Gigot, B. Navez, C. Lambert et al., Does the site of platelet sequestration predict the response to splenectomy in adult patients with immune thrombocytopenic purpura?, Platelets, vol.5, issue.6, pp.573-579, 2015.
DOI : 10.1182/blood-2003-11-3908

L. Thai, M. Mahévas, F. Roudot-thoraval, N. Limal, L. Languille et al., Long-term complications of splenectomy in adult immune thrombocytopenia, Medicine, vol.95, issue.48, p.5098, 2016.
DOI : 10.1097/MD.0000000000005098

E. Meriglier, M. Puyade, M. Carretier, F. Roblot, and P. Roblot, Complications infectieuses ?? long terme des patients spl??nectomis??s??: cohorte r??trospective avec un suivi de plus de 10??ans, La Revue de M??decine Interne, vol.38, issue.7, pp.436-479, 2017.
DOI : 10.1016/j.revmed.2016.12.023

R. Buzelé, L. Barbier, A. Sauvanet, and B. Fantin, Complications m??dicales des spl??nectomies, Journal de Chirurgie Visc??rale, vol.153, issue.4, pp.289-99, 2016.
DOI : 10.1016/j.jchirv.2016.03.011

M. Rørholt, W. Ghanima, D. Farkas, and M. Nørgaard, Risk of cardiovascular events and pulmonary hypertension following splenectomy ??? a Danish population-based cohort study from 1996???2012, Haematologica, vol.102, issue.8, pp.1333-1374, 2017.
DOI : 10.3324/haematol.2016.157008

J. Redman, E. Hill, D. Aldeghaither, and L. Weiner, Mechanisms of action of therapeutic antibodies for cancer, Molecular Immunology, vol.67, issue.2, pp.28-45, 2015.
DOI : 10.1016/j.molimm.2015.04.002

D. Arnold, J. Vrbensky, N. Karim, J. Smith, Y. Liu et al., The effect of rituximab on anti-platelet autoantibody levels in patients with immune thrombocytopenia, British Journal of Haematology, vol.67, issue.Suppl 1, pp.302-309, 2017.
DOI : 10.1136/ard.2007.087478

R. Stasi, D. Poeta, G. Stipa, E. Evangelista, M. Trawinska et al., Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura, Blood, vol.110, issue.8, pp.2924-2954, 2007.
DOI : 10.1182/blood-2007-02-068999

R. Stasi, A. Pagano, E. Stipa, and S. Amadori, Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood, pp.952-959, 2001.

M. Mahévas, M. Ebbo, S. Audia, B. Bonnotte, N. Schleinitz et al., Efficacy and safety of rituximab given at 1,000 mg on days 1 and 15 compared to the standard regimen to treat adult immune thrombocytopenia, American Journal of Hematology, vol.87, issue.10, pp.858-61, 2013.
DOI : 10.1002/ajh.23272

M. Khellaf, A. Charles-nelson, O. Fain, L. Terriou, J. Viallard et al., Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients, Blood, vol.124, issue.22, pp.3228-3264, 2014.
DOI : 10.1182/blood-2014-06-582346

V. Patel, M. Mahévas, S. Lee, R. Stasi, S. Cunningham-rundles et al., Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood, pp.5989-95, 2012.

R. Feng, X. Liu, Y. Zhao, Y. Zhu, J. Peng et al., GPIIb/IIIa autoantibody predicts better rituximab response in ITP, British Journal of Haematology, vol.87, 2017.
DOI : 10.1002/ajh.22211

R. Looney, R. Srinivasan, and L. Calabrese, The effects of rituximab on immunocompetency in patients with autoimmune disease, Arthritis & Rheumatism, vol.3, issue.1, pp.5-14, 2008.
DOI : 10.1002/art.23171

D. Kuter, The biology of thrombopoietin and thrombopoietin receptor agonists, International Journal of Hematology, vol.110, issue.s1, pp.10-23, 2013.
DOI : 10.1046/j.1365-2141.2000.02169.x

F. Rodeghiero and G. Carli, Beyond immune thrombocytopenia: the evolving role of thrombopoietin receptor agonists, Annals of Hematology, vol.126, issue.s1, 2017.
DOI : 10.1182/blood-2014-09-602573

D. Kuter, J. Bussel, R. Lyons, V. Pullarkat, T. Gernsheimer et al., Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial, The Lancet, vol.371, issue.9610, pp.395-403, 2008.
DOI : 10.1016/S0140-6736(08)60203-2

B. Wang, J. Nichol, and J. Sullivan, Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand, Clinical Pharmacology & Therapeutics, vol.76, issue.6, pp.628-666, 2004.
DOI : 10.1016/j.clpt.2004.08.010

D. Kuter, M. Rummel, R. Boccia, B. Macik, I. Pabinger et al., Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia, New England Journal of Medicine, vol.363, issue.20, pp.1889-99, 2010.
DOI : 10.1056/NEJMoa1002625

D. Kuter, J. Bussel, A. Newland, R. Baker, R. Lyons et al., Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy, British Journal of Haematology, vol.362, issue.Suppl. 2, pp.411-434, 2013.
DOI : 10.1056/NEJMcpc0910931

D. Kuter, S. Mathias, M. Rummel, R. Mandanas, A. Giagounidis et al., Health-related quality of life in nonsplenectomized immune thrombocytopenia patients receiving romiplostim or medical standard of care, American Journal of Hematology, vol.87, issue.5, pp.558-61, 2012.
DOI : 10.1002/ajh.23163

F. Rodeghiero, R. Stasi, A. Giagounidis, J. Viallard, B. Godeau et al., Long-term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials, European Journal of Haematology, vol.357, issue.5, pp.423-459, 2013.
DOI : 10.1056/NEJMoa073275

D. Kuter, G. Mufti, B. Bain, R. Hasserjian, W. Davis et al., Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim. Blood, pp.3748-56, 2009.

M. Saleh, J. Bussel, G. Cheng, O. Meyer, C. Bailey et al., Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study, Blood, vol.121, issue.3, pp.537-582, 2013.
DOI : 10.1182/blood-2012-04-425512

R. Brynes, A. Orazi, D. Theodore, P. Burgess, C. Bailey et al., Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenia treated with eltrombopag: Data from the EXTEND study, American Journal of Hematology, vol.15, issue.7, pp.598-601, 2015.
DOI : 10.1177/096120339700600412

L. Ehrlich, V. Kwitkowski, G. Reaman, C. Ko, L. Nie et al., Food and Drug Administration approval summary: Eltrombopag for the treatment of pediatric patients with chronic immune (idiopathic) thrombocytopenia. Pediatr Blood Cancer

A. Contis, E. Lazaro, C. Greib, J. Pellegrin, and J. Viallard, Romiplostim as early treatment for refractory primary immune thrombocytopenia, International Journal of Hematology, vol.149, issue.5, pp.520-524, 2013.
DOI : 10.1111/j.1365-2141.2010.08092.x

M. Khellaf, J. Viallard, M. Hamidou, S. Cheze, F. Roudot-thoraval et al., A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia, Haematologica, vol.98, issue.6, pp.881-888, 2013.
DOI : 10.3324/haematol.2012.074633

E. Weber, G. Moulis, M. Mahévas, C. Guy, B. Lioger et al., Thrombosis during thrombopoietin receptor agonist treatment for immune thrombocytopenia. A French multicentric observational study], Rev Med Interne, 2016.

M. Hilgartner, P. Lanzkowsky, and C. Smith, THE USE OF AZATHIOPRINE IN REFRACTORY IDIOPATHIC THROMBOCYTOPENIC PURPURA IN CHILDREN, Acta Paediatrica, vol.277, issue.4, pp.409-424, 1970.
DOI : 10.1001/jama.202.4.259

I. Quiquandon, P. Fenaux, M. Caulier, D. Pagniez, J. Huart et al., Re-evaluation of the role of azathioprine in the treatment of adult chronic idiopathic thrombocytopenic purpura: a report on 53 cases, British Journal of Haematology, vol.53, issue.2, pp.223-231, 1990.
DOI : 10.1002/ajh.2830010111

A. Reiner, T. Gernsheimer, and S. Slichter, Pulse cyclophosphamide therapy for refractory autoimmune thrombocytopenic purpura [see comments]. Blood, pp.351-359, 1995.

É. Thervet, J. Zuber, R. Sberro, G. Canaud, D. Anglicheau et al., Traitements immunosuppresseurs : mécanismes d'action et utilisation clinique, p.37, 2011.

D. Choudhary, R. Naithani, M. Mahapatra, R. Kumar, P. Mishra et al., Efficacy of cyclosporine as a single agent therapy in chronic idiopathic thrombocytopenic purpura, Haematologica, vol.93, issue.10, pp.61-63, 2008.
DOI : 10.3324/haematol.13481

W. Liu, X. Gu, R. Fu, Y. Li, M. Lv et al., The Effect of Danazol in Primary Immune Thrombocytopenia, Clinical and Applied Thrombosis/Hemostasis, vol.29, issue.6, pp.727-760, 2016.
DOI : 10.1016/S0168-8278(98)80140-2

F. Maloisel, E. Andrès, J. Zimmer, E. Noel, A. Zamfir et al., Danazol therapy in patients with chronic idiopathic thrombocytopenic purpura: long-term results, The American Journal of Medicine, vol.116, issue.9
DOI : 10.1016/j.amjmed.2003.12.024

Q. Hill, How does dapsone work in immune thrombocytopenia? Implications for dosing. Blood, pp.3666-3674, 2015.

C. Rodrigo and L. Gooneratne, Dapsone for primary immune thrombocytopenia in adults and children: an evidence-based review, Journal of Thrombosis and Haemostasis, vol.73, issue.11, pp.1946-53, 2013.
DOI : 10.1097/00043426-200302000-00019

C. Tang, T. Godfrey, R. Stawell, and M. Nikpour, Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects, Internal Medicine Journal, vol.4, issue.1, pp.968-78, 2012.
DOI : 10.1016/j.autrev.2004.11.009

M. Khellaf, A. Chabrol, M. Mahevas, F. Roudot-thoraval, N. Limal et al., Hydroxychloroquine is a good second-line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies, American Journal of Hematology, vol.54, issue.2, 2014.
DOI : 10.1002/art.22156

D. Provan, A. Moss, A. Newland, and J. Bussel, Efficacy of mycophenolate mofetil as single-agent therapy for refractory immune thrombocytopenic purpura, American Journal of Hematology, vol.125, issue.1, pp.19-25, 2006.
DOI : 10.7326/0003-4819-126-4-199702150-00007

M. Hou, J. Peng, Y. Shi, C. Zhang, P. Qin et al., Mycophenolate mofetil (MMF) for the treatment of steroid-resistant idiopathic thrombocytopenic purpura, European Journal of Haematology, vol.70, issue.6, pp.353-360, 2003.
DOI : 10.1034/j.1600-0609.2003.00076.x

A. Taylor, L. Neave, S. Solanki, J. Westwood, I. Terrinonive et al., Mycophenolate mofetil therapy for severe immune thrombocytopenia, British Journal of Haematology, vol.96, issue.4, 2015.
DOI : 10.1097/TP.0b013e31828c6dc7

URL : http://onlinelibrary.wiley.com/doi/10.1111/bjh.13622/pdf

M. Miano, M. Scalzone, K. Perri, E. Palmisani, I. Caviglia et al., Mycophenolate mofetil and Sirolimus as second or further line treatment in children with chronic refractory Primitive or Secondary Autoimmune Cytopenias: a single centre experience, British Journal of Haematology, vol.26, issue.22, pp.247-53, 2015.
DOI : 10.1111/j.1745-7254.2005.00088.x

M. Miano, U. Ramenghi, G. Russo, L. Rubert, A. Barone et al., Mycophenolate mofetil for the treatment of children with??immune thrombocytopenia and Evans syndrome. A retrospective data review from the Italian association of paediatric haematology/oncology, British Journal of Haematology, vol.26, issue.3, pp.490-495, 2016.
DOI : 10.1111/j.1745-7254.2005.00088.x

R. Goel, P. Ness, C. Takemoto, L. Krishnamurti, K. King et al., Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortality. Blood, Feb, vol.26125, issue.9, pp.1470-1476, 2015.

B. Fresneau, A. Petit, M. Courcoux, M. Tabone, A. Auvrignon et al., Vinblastine in the treatment of children and adolescents with refractory immune thrombocytopenia, American Journal of Hematology, vol.86, issue.9, pp.785-792, 2011.
DOI : 10.1002/ajh.22081

J. Stirnemann, N. Kaddouri, M. Khellaf, A. Morin, V. Prendki et al., Vincristine efficacy and safety in treating immune thrombocytopenia: a retrospective study of 35 patients, European Journal of Haematology, vol.146, issue.3, pp.269-75, 2016.
DOI : 10.7326/0003-4819-146-1-200701020-00006

C. Barnes, V. Blanchette, P. Canning, and M. Carcao, Recombinant FVIIa in the management of intracerebral haemorrhage in severe thrombocytopenia unresponsive to platelet-enhancing treatment, Transfusion Medicine, vol.100, issue.2, pp.145-50, 2005.
DOI : 10.1046/j.1365-2516.2000.00345.x

A. Altintas, A. Ozel, N. Okur, N. Okur, T. Cil et al., Prevalence and clinical significance of elevated antinuclear antibody test in children and adult patients with idiopathic thrombocytopenic purpura, Journal of Thrombosis and Thrombolysis, vol.118, issue.2, pp.163-171, 2007.
DOI : 10.2169/internalmedicine1962.29.481

S. Zimmerman and R. Ware, Clinical Significance of the Antinuclear Antibody Test in Selected Children with Idiopathic Thrombocytopenic Purpura, Journal of Pediatric Hematology/Oncology, vol.19, issue.4, 1997.
DOI : 10.1097/00043426-199707000-00006

J. Nossent and A. Swaak, Prevalence and significance of haematological abnormalities in patients with systemic lupus erythematosus, Q J Med, vol.80, issue.291, pp.605-617, 1991.

D. Cines, H. Liebman, and R. Stasi, Pathobiology of Secondary Immune Thrombocytopenia, Seminars in Hematology, vol.46, issue.1 2, pp.2-14, 2009.
DOI : 10.1053/j.seminhematol.2008.12.005

R. Stasi, E. Stipa, M. Masi, F. Oliva, A. Sciarra et al., Prevalence and clinical significance of elevated antiphospholipid antibodies in patients with idiopathic thrombocytopenic purpura. Blood, pp.4203-4211, 1994.

C. Bidot, W. Jy, L. Horstman, E. Ahn, J. Jimenez et al., Antiphospholipid antibodies in immune thrombocytopenic purpura tend to emerge in exacerbation and decline in remission, British Journal of Haematology, vol.75, issue.3, pp.366-72, 2005.
DOI : 10.1002/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F

G. Moulis, A. Audemard-verger, L. Arnaud, C. Luxembourger, F. Montastruc et al., Risk of thrombosis in patients with primary immune thrombocytopenia and antiphospholipid antibodies: A systematic review and meta-analysis, Autoimmunity Reviews, vol.15, issue.3, pp.203-212, 2016.
DOI : 10.1016/j.autrev.2015.11.001

B. Godeau, J. Piette, P. Fromont, L. Intrator, A. Schaeffer et al., Specific antiplatelet glycoprotein autoantibodies are associated with the thrombocytopenia of primary antiphospholipid syndrome, British Journal of Haematology, vol.98, issue.4, pp.873-882, 1997.
DOI : 10.1046/j.1365-2141.1997.3063123.x

M. Miano, How I manage Evans Syndrome and AIHA cases in children, British Journal of Haematology, vol.26, issue.5 Suppl., pp.524-558
DOI : 10.1111/j.1745-7254.2005.00088.x

N. Aladjidi, H. Fernandes, T. Leblanc, A. Vareliette, F. Rieux-laucat et al., Evans Syndrome in Children: Long-Term Outcome in a Prospective French National Observational Cohort, Frontiers in Pediatrics, vol.124, issue.10, p.79, 2015.
DOI : 10.1182/blood-2014-02-553834

A. Loachimescu, A. Makdissi, A. Lichtin, and R. Zimmerman, Thyroid Disease in Patients with Idiopathic Thrombocytopenia: A Cohort Study, Thyroid, vol.17, issue.11, pp.1137-1179, 2007.
DOI : 10.1089/thy.2007.0066

I. Cordiano, C. Betterle, C. Spadaccino, B. Soini, A. Girolami et al., Autoimmune thrombocytopenia (AITP) and thyroid autoimmune disease (TAD): overlapping syndromes? Clin Exp Immunol, pp.373-381, 1998.
DOI : 10.1046/j.1365-2249.1998.00677.x

URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1905072/pdf

H. Tahir, F. Sheraz, J. Sagi, and V. Daruwalla, Immune Thrombocytopenia (ITP) Secondary to Subclinical Hashimoto???s Thyroiditis, Journal of Investigative Medicine High Impact Case Reports, vol.26, issue.4, 2016.
DOI : 10.1007/s10067-007-0602-5

L. Westh, T. Mogensen, L. Dalgaard, B. Jensen, J. Katzenstein et al., Identification and Characterization of a Nationwide Danish Adult Common Variable Immunodeficiency Cohort, Scandinavian Journal of Immunology, vol.104, issue.6, pp.450-61, 2017.
DOI : 10.1016/S0091-6749(99)70085-0

K. Warnatz, A. Denz, R. Dräger, M. Braun, C. Groth et al., Severe deficiency of switched memory B cells (CD27+IgM-IgD-) in subgroups of patients with common variable immunodeficiency: a new approach to classify a heterogeneous disease, Blood, vol.99, issue.5, pp.1544-51, 2002.
DOI : 10.1182/blood.V99.5.1544

L. Wang, Y. Li, and M. Hou, Idiopathic thrombocytopenic purpura and dysmegakaryocytopoiesis, Critical Reviews in Oncology/Hematology, vol.64, issue.2, pp.83-92, 2007.
DOI : 10.1016/j.critrevonc.2007.05.007

J. Oliveira, J. Bleesing, U. Dianzani, T. Fleisher, E. Jaffe et al., Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop, Blood, vol.116, issue.14, pp.35-40, 2010.
DOI : 10.1182/blood-2010-04-280347

V. Price, Auto-immune lymphoproliferative disorder and other secondary immune thrombocytopenias in childhood, Pediatric Blood & Cancer, vol.145, issue.S1, pp.12-14, 2013.
DOI : 10.1111/j.1365-2141.2009.07595.x

G. Landonio, L. Cirasino, A. Prete, A. Nosari, and M. Imbriani, Thrombocytopenia (TP) in HIV infection, European Journal of Haematology, vol.4, issue.4, pp.239-279, 1993.
DOI : 10.1111/j.1600-0609.1993.tb01928.x

E. Sloand, H. Klein, S. Banks, B. Vareldzis, S. Merritt et al., Epidemiology of thrombocytopenia in HIV inlection, European Journal of Haematology, vol.108, issue.5, pp.168-72, 1992.
DOI : 10.7326/0003-4819-108-2-175

A. Hohmann, K. Booth, V. Peters, R. Comacchio, and D. Gordon, Common epitope on HIV p24 and human platelets. The Lancet, pp.1274-1279, 1993.

E. Virot, A. Duclos, L. Adelaide, P. Miailhes, A. Hot et al., Autoimmune diseases and HIV infection, Medicine, vol.96, issue.4, p.5769
DOI : 10.1097/MD.0000000000005769

T. Nagamine, T. Ohtuka, K. Takehara, T. Arai, H. Takagi et al., Thrombocytopenia associated with hepatitis C viral infection, Journal of Hepatology, vol.24, issue.2, pp.135-175, 1996.
DOI : 10.1016/S0168-8278(96)80021-3

H. Liebman, Viral-Associated Immune Thrombocytopenic Purpura. ASH Educ Program Book, pp.212-220, 2008.

G. Bordin, M. Ballaré, P. Zigrossi, M. Bertoncelli, L. Paccagnino et al., A laboratory and thrombokinetic study of HCV-associated thrombocytopenia: a direct role of HCV in bone marrow exhaustion?, Clin Exp Rheumatol, vol.13, pp.39-43, 1995.

C. Burness, Eltrombopag: A Review of Its Use in the Treatment of Thrombocytopenia in Patients with Chronic Hepatitis C, Drugs, vol.56, issue.Suppl 4, pp.1961-71, 2014.
DOI : 10.1111/j.1365-2125.2011.03972.x

D. Dimaggio, A. Anderson, and J. Bussel, Cytomegalovirus can make immune thrombocytopenic purpura refractory, British Journal of Haematology, vol.19, issue.355, pp.104-116, 2009.
DOI : 10.2177/jsci.20.134

C. Hsiao, Epstein-Barr virus associated with immune thrombocytopenic purpura in childhood: A retrospective study, Journal of Paediatrics and Child Health, vol.36, issue.5, pp.445-453, 2000.
DOI : 10.1046/j.1440-1754.2000.00539.x

T. Steeper, C. Horwitz, S. Moore, W. Henle, G. Henle et al., Severe thrombocytopenia in Epstein-Barr virus-induced mononucleosis, West J Med, 1989.

M. Rand and J. Wright, Virus-associated Idiopathic Thrombocytopenic Purpura, Transfusion Science, vol.19, issue.3, pp.253-262, 1998.
DOI : 10.1016/S0955-3886(98)00039-3

Y. Cheng, L. Kuang, C. Zhuang, J. Jiang, and M. Shi, Effects of cytotoxin-associated gene A (CagA) positive Helicobacter pylori infection on anti-platelet glycoprotein antibody producing B cells in patients with primary idiopathic thrombocytopenic purpura (ITP), Pak J Med Sci, vol.31, issue.1, pp.121-127, 2015.

R. Stasi and D. Provan, Helicobacter pylori and Chronic ITP, Hematology, vol.2008, issue.1, pp.206-217, 2008.
DOI : 10.1182/asheducation-2008.1.206

C. Perricone, F. Ceccarelli, G. Nesher, E. Borella, Q. Odeh et al., Immune thrombocytopenic purpura (ITP) associated with vaccinations: a review of reported cases, Immunologic Research, vol.2013, issue.62, pp.2-3226, 2014.
DOI : 10.1038/sj.bmt.1705442

J. Rajantie, B. Zeller, I. Treutiger, and S. Rosthöj, Vaccination associated thrombocytopenic purpura in children. Vaccine, Feb, vol.2625, issue.10, pp.1838-1878, 2007.

N. Okazaki, M. Takeguchi, K. Sonoda, Y. Handa, T. Kakiuchi et al., Detection of platelet-binding anti-measles and anti-rubella virus IgG antibodies in infants with vaccine-induced thrombocytopenic purpura, Vaccine, vol.29, issue.31, pp.4878-80, 2011.
DOI : 10.1016/j.vaccine.2011.04.036

O. Leary, S. Glanz, J. Mcclure, D. Akhtar, A. Daley et al., The Risk of Immune Thrombocytopenic Purpura After Vaccination in Children and Adolescents. Pediatrics, Feb, vol.1129, issue.2, pp.248-55, 2012.

C. Black, J. Kaye, and H. Jick, MMR vaccine and idiopathic thrombocytopaenic purpura, British Journal of Clinical Pharmacology, vol.322, issue.1, pp.107-118, 2003.
DOI : 10.1097/00006454-199601000-00010

C. Visco, W. Barcellini, F. Maura, A. Neri, A. Cortelezzi et al., Autoimmune cytopenias in chronic lymphocytic leukemia, American Journal of Hematology, vol.123, issue.11, pp.1055-62, 2014.
DOI : 10.1046/j.1365-2141.2003.04609.x

K. Rogers, A. Ruppert, A. Bingman, L. Andritsos, F. Awan et al., Incidence and Description of Autoimmune Cytopenias During Treatment with Ibrutinib for Chronic Lymphocytic Leukemia Autoimmune Cytopenias During Ibrutinib Treatment, Leukemia. Feb, vol.30, issue.2, pp.346-50, 2016.

M. Fallah, X. Liu, J. J. Försti, A. Sundquist, K. Hemminki et al., Autoimmune diseases associated with non-Hodgkin lymphoma: a nationwide cohort study, Annals of Oncology, vol.25, issue.10, pp.2025-2055, 2014.
DOI : 10.1093/annonc/mdu365

A. Hauswirth, C. Skrabs, C. Schützinger, M. Raderer, A. Chott et al., Autoimmune thrombocytopenia in non-Hodgkin's lymphomas. Haematologica, pp.447-50, 2008.

E. Faller, L. Chapman, H. Enright, P. Browne, J. Mchugh et al., Immune thrombocytopenia purpura associated with multiple myeloma, Annals of Hematology, vol.13, issue.8, p.2016
DOI : 10.1016/j.intimp.2012.04.015

G. Moulis, J. Germain, T. Comont, N. Brun, C. Dingremont et al., Newly diagnosed immune thrombocytopenia adults: Clinical epidemiology, exposure to treatments, and evolution. Results of the CARMEN multicenter prospective cohort, American Journal of Hematology, vol.128, issue.6, pp.493-500
DOI : 10.1016/j.imlet.2011.06.001

S. Daou, L. Federici, J. Zimmer, F. Maloisel, K. Serraj et al., Idiopathic thrombocytopenic purpura in elderly patients: A study of 47 cases from a single reference center, European Journal of Internal Medicine, vol.19, issue.6, pp.447-51, 2008.
DOI : 10.1016/j.ejim.2007.07.006

V. Rieu, M. Ruivard, C. Chaleteix, O. Tournilhac, and P. P. , Purpura thrombopénique immunologique chez les patients âgés. Httpwwwem-Premiumcomdocelecu- Bordeauxfrdatarevues02488663002900S308009752 [Internet], p.270, 2008.

A. Zulfiqar, J. Novella, R. Mahmoudi, J. Pennaforte, and E. Andres, Treatment in idiopathic thrombocytopenic purpura in the elderly: about a retrospective study. Geriatr Psychol Neuropsychiatr Vieil, pp.151-158, 2016.

M. Mahévas, M. Michel, and B. Godeau, How we manage immune thrombocytopenia in the elderly, British Journal of Haematology, vol.92, issue.6, pp.844-56
DOI : 10.1007/s00277-012-1567-2

L. Grimaldi-bensouda, C. Nordon, T. Leblanc, L. Abenhaim, S. Allali et al., Childhood immune thrombocytopenia: A nationwide cohort study on condition management and outcomes. Pediatr Blood Cancer, 2017.

T. Kühne, J. Freedman, J. Semple, J. Doyle, S. Butchart et al., Platelet and immune responses to oral cyclic dexamethasone therapy in childhood chronic immune thrombocytopenic purpura, The Journal of Pediatrics, vol.130, issue.1, pp.17-24, 1997.
DOI : 10.1016/S0022-3476(97)70305-6

V. Cecinati, N. Principi, L. Brescia, P. Giordano, and S. Esposito, Vaccine administration and the development of immune thrombocytopenic purpura in children. Hum Vaccines Immunother, pp.1158-62, 2013.

M. Charlson, P. Pompei, K. Ales, and C. Mackenzie, A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation, Journal of Chronic Diseases, vol.40, issue.5, pp.373-83, 1987.
DOI : 10.1016/0021-9681(87)90171-8

F. Buntinx, L. Niclaes, C. Suetens, B. Jans, R. Mertens et al., Evaluation of Charlson's comorbidity index in elderly living in nursing homes, Journal of Clinical Epidemiology, vol.55, issue.11, pp.1144-1151, 2002.
DOI : 10.1016/S0895-4356(02)00485-7

L. Bizzoni, M. Mazzucconi, M. Gentile, C. Santoro, S. Bernasconi et al., Idiopathic thrombocytopenic purpura (ITP) in the elderly: clinical course in 178 patients, European Journal of Haematology, vol.33, issue.3, pp.210-216, 2006.
DOI : 10.1016/S0145-2126(02)00056-5

L. Page, B. Psaila, D. Provan, M. Hamilton, J. Jenkins et al., The immune thrombocytopenic purpura (ITP) bleeding score: assessment of bleeding in patients with ITP, British Journal of Haematology, vol.35, issue.Suppl. 1, pp.245-253, 2007.
DOI : 10.1111/j.1365-2141.2007.06635.x

H. Tsuda, T. Tsuji, M. Tsuji, and H. Yamasaki, Life-threatening bleeding episodes in primary immune thrombocytopenia: a single-center retrospective study of 169 inpatients, Annals of Hematology, vol.114, issue.Pt B, pp.1-6, 2017.
DOI : 10.1182/blood-2009-04-215525

Y. Kurata, S. Miyagawa, S. Kosugi, H. Kashiwagi, S. Honda et al., High-titer antinuclear antibodies, anti-SSA/Ro antibodies and anti-nuclear RNP antibodies in patients with idiopathic thrombocytopenic purpura, Thromb Haemost, 1994.

F. Tosato, G. Bucciol, G. Pantano, M. Putti, M. Sanzari et al., Lymphocytes subsets reference values in childhood, Cytometry Part A, vol.27, issue.1, 2015.
DOI : 10.3109/10408368909106595

R. Talaat, A. Elmaghraby, S. Barakat, and M. El-shahat, Alterations in immune cell subsets and their cytokine secretion profile in childhood idiopathic thrombocytopenic purpura (ITP), Clinical & Experimental Immunology, vol.62, issue.Suppl. 9, pp.291-300, 2014.
DOI : 10.1016/0165-5728(95)00115-9

J. Garcia-suarez, A. Prieto, E. Reyes, L. Manzano, J. Merino et al., Severe chronic autoimmune thrombocytopenic purpura is associated with an expansion of CD56+ CD3-natural killer cells subset [see comments]. Blood, pp.1538-1583, 1993.

M. Ebbo, S. Audonnet, A. Grados, L. Benarous, M. Mahevas et al., NK cell compartment in the peripheral blood and spleen in adult patients with primary immune thrombocytopenia, Clinical Immunology, vol.177, pp.18-28
DOI : 10.1016/j.clim.2015.11.005

P. Sansoni, A. Cossarizza, V. Brianti, F. Fagnoni, G. Snelli et al., Lymphocyte subsets and natural killer cell activity in healthy old people and centenarians [see comments]. Blood, pp.2767-73, 1993.

L. Ginaldi, D. Martinis, M. , D. Ostilio, A. Marini et al., Changes in the expression of surface receptors on lymphocyte subsets in the elderly: Quantitative flow cytometric analysis, American Journal of Hematology, vol.11, issue.2, pp.63-72, 2001.
DOI : 10.1038/sj.leu.2400835

P. Sansoni, R. Vescovini, F. Fagnoni, C. Biasini, F. Zanni et al., The immune system in extreme longevity, Experimental Gerontology, vol.43, issue.2, pp.61-66, 2008.
DOI : 10.1016/j.exger.2007.06.008

A. Faria, S. De-moraes, L. De-freitas, E. Speziali, T. Soares et al., Variation rhythms of lymphocyte subsets during healthy aging, Neuroimmunomodulation, vol.15, pp.4-6365, 2008.

B. Weinberger, L. Lazuardi, I. Weiskirchner, M. Keller, C. Neuner et al., Healthy Aging and Latent Infection with CMV Lead to Distinct Changes in CD8+ and CD4+ T-Cell Subsets in the Elderly, Human Immunology, vol.68, issue.2, pp.86-90, 2007.
DOI : 10.1016/j.humimm.2006.10.019

Y. Najean, J. Rain, and C. Billotey, The site of destruction of autologous 111In-labelled platelets and the efficiency of splenectomy in children and adults with idiopathic thrombocytopenic purpura: a study of 578 patients with 268 splenectomies, British Journal of Haematology, vol.97, issue.3, pp.547-50, 1997.
DOI : 10.1046/j.1365-2141.1997.832723.x

H. Zhou, R. Fu, H. Wang, F. Zhou, H. Li et al., Immune thrombocytopenia in the elderly: clinical course in 525 patients from a single center in China, Annals of Hematology, vol.2, issue.7040, 2013.
DOI : 10.1016/S0140-6736(58)90057-6

C. Bennett, C. Neunert, R. Grace, G. Buchanan, P. Imbach et al., Predictors of remission in children with newly diagnosed immune thrombocytopenia: Data from the Intercontinental Cooperative ITP Study Group Registry II participants, Pediatric Blood & Cancer, vol.101, issue.7, 2009.
DOI : 10.1111/j.1651-2227.2012.02671.x

M. Michel, F. Suzan, D. Adoue, D. Bordessoule, J. Marolleau et al., Management of immune thrombocytopenia in adults: a population-based analysis of the French hospital discharge database from 2009 to 2012, British Journal of Haematology, vol.75, issue.2, pp.218-240, 2009.
DOI : 10.1002/ajh.10445